Mr Reginald Robert Sherrill, MD in Dalton, GA - Medicare Plastic And Reconstructive Surgery

Mr Reginald Robert Sherrill, MD is a medicare enrolled "Plastic Surgery" physician in Dalton, Georgia. He went to Loma Linda University School Of Medicine and graduated in 1977 and has 47 years of diverse experience with area of expertise as Plastic And Reconstructive Surgery. His current practice location is 1501 Broadrick Dr, Suite 1, Dalton, Georgia. You can reach out to his office (for appointments etc.) via phone at (706) 226-3311.

Mr Reginald Robert Sherrill is licensed to practice in Georgia (license number 023677) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1528007663.

Contact Information

	Mr Reginald Robert Sherrill, MD
	1501 Broadrick Dr, Suite 1, Dalton, GA 30720-3014
	(706) 226-3311
	(706) 275-8723

Physician's Profile

Full Name	Mr Reginald Robert Sherrill
Gender	Male
Speciality	Plastic And Reconstructive Surgery
Experience	47 Years
Location	1501 Broadrick Dr, Dalton, Georgia
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Mr Reginald Robert Sherrill attended and graduated from Loma Linda University School Of Medicine in 1977

NPI Data:

NPI Number: 1528007663
Provider Enumeration Date: 06/05/2006
Last Update Date: 03/19/2010

Medicare PECOS Information:

PECOS PAC ID: 5991994725
Enrollment ID: I20110111000115

Medical Identifiers

Medical identifiers for Mr Reginald Robert Sherrill such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1528007663	NPI	-	NPPES
023677	Other	GA	GA LICENSE
00245627A	Medicaid	GA
208200000X	Other	GA	PROVIDER TYPE

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208200000X	Plastic Surgery	023677 (Georgia)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Hamilton Medical Center	Dalton, GA	Hospital

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr Reginald Robert Sherrill is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr Reginald Robert Sherrill, MD 1501 Broadrick Dr, Suite 1, Dalton, GA 30720-3014 Ph: (706) 226-3311	Mr Reginald Robert Sherrill, MD 1501 Broadrick Dr, Suite 1, Dalton, GA 30720-3014 Ph: (706) 226-3311

News Archive

Insulin pump therapy can benefit all type 1 diabetes patients

Insulin pump therapy contributes to better blood glucose control in type 1 diabetes and, as pump technology continues to improve and become part of sensor-controlled feedback and artificial pancreas systems, essentially all patients would benefit from their capabilities according to a Commentary published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

FDA assigns PDUFA action date for Orexigen's Contrave NDA review

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).

Health-tech startups expanding innovations one year after completing Cedars-Sinai Accelerator program

One year after graduating from the Cedars-Sinai Accelerator powered by Techstars, several health-tech startups are swiftly expanding their innovations into hospitals and other healthcare settings for the benefit of patients.

Tolerx enters collaborative research agreement with Cancer Research Institute

Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

New path involving "innocent spectators" to defeat systemic sclerosis

There is a new path to defeat systemic sclerosis, also called scleroderma because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent spectators," as Catholic University rheumatologist Gianfranco Ferraccioli, among the authors of the important research, puts it.

Mr Reginald Robert Sherrill, MD - Medicare Plastic And Reconstructive Surgery in Dalton, GA